Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 61Myelodysplastic Syndromes 52Recurrence 37Leukemia, Lymphocytic, Chronic, B-Cell 37Multiple Myeloma 36Lymphoma, Non-Hodgkin 35Lymphoma 34Lymphoma, B-Cell 29Hematologic Neoplasms 28Lymphoma, Follicular 24Lymphoma, Large B-Cell, Diffuse 23Lymphoma, Mantle-Cell 22Leukemia 22Melanoma 21Lymphoma, B-Cell, Marginal Zone 20Myeloproliferative Disorders 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 19Leukemia, Biphenotypic, Acute 18Hodgkin Disease 18Ovarian Neoplasms 17Burkitt Lymphoma 17Pancreatic Neoplasms 16Neoplasms 13Neoplasm Metastasis 12Leukemia, Myelomonocytic, Chronic 12Colorectal Neoplasms 11Anemia, Refractory, with Excess of Blasts 11Stomach Neoplasms 10Carcinoma, Non-Small-Cell Lung 10

Interventions

fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Muscular Diseases × fludarabine × 1 year × Clear all
NCT06626919 2026-02-25

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Arcellx, Inc.

Phase 1 Recruiting
30 enrolled

Autoimmune Diseases, Muscular Diseases, Myasthenia Gravis, Muscle Weakness, Autoimmune Diseases of the Nervous System, Neuromuscular Manifestations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡